The Trump Administration's Move to End Subsidies for Medicare Drug Plans Could Cost Consumers Dearly The latest proposal from the Trump administration to end subsidies for Medicare drug plans has sent shockwaves through the healthcare community, sparking concerns about the potential impact on vulnerable seniors and people with disabilities.
At its core, this decision is a cost saving measure that could have far reaching consequences for those who rely on these programs.
Removing subsidies for Medicare drug plans would likely result in increased costs for consumers, particularly low income seniors and those with limited financial resources.